No Data
Shandong Buchang Pharmaceuticals (603858.SH): has accumulated a buyback of 0.20% of the company's shares.
On March 4, Glonghui reported that Shandong Buchang Pharmaceuticals (603858.SH) announced that as of February 28, 2025, the company has repurchased a total of 2,187,830 shares through centralized bidding in the Trade, accounting for 0.20% of the company's total share capital. The highest purchase price was 14.96 yuan/share, the lowest price was 14.55 yuan/share, and the total amount paid to date was 32,430,482.65 yuan (excluding transaction fees). The difference in the percentage of repurchased shares is due to rounding.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Shandong Buchang Pharmaceuticals (603858.SH) plans to give up the priority to acquire shares in the investment Fund.
On February 25, Gu Longhui reported that Shandong Buchang Pharmaceuticals (603858.SH) announced that as a limited partner, it participated in the subscription investment of the investment fund Yuanhe Puhua Limited Partnership in the CNI Yangtze Index Coordinated Advantage Industry Private Equity Partnership (Limited Partnership). It plans to transfer its unpaid fund share of 50 million yuan to Guangzhou Dongjin Licreat at a price of 0 yuan, plans to transfer its unpaid fund share of 30 million yuan to Liangxi Kechuang Investment at a price of 0 yuan, and plans to transfer its unpaid fund share of 20 million yuan to Ningbo Hongning HENG TAI at a price of 0 yuan; the limited partner Suzhou Innovation Industry Development Guidance Fund (
Shandong Buchang Pharmaceuticals Gets Regulatory Approval for Drug Manufacturing License Changes
Buchang Pharmaceuticals Subsidiary Completes Industrial, Commercial Registration
Shandong Buchang Pharmaceuticals (603858.SH): Deregistration of the affiliated company Peking Kuangfang.
Gelonghui, February 10th丨Shandong Buchang Pharmaceuticals (603858.SH) announced that its affiliated company, Peking Kuangfang Technology Co., Ltd. (abbreviated as "Peking Kuangfang"), has completed the cancellation of business registration and received the "Cancellation Approval Notice" issued by the Market Supervision Administration of Miyun District, Peking.
Shandong Buchang Pharmaceuticals (SHSE:603858) Shareholders Have Endured a 15% Loss From Investing in the Stock Three Years Ago
